Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDAPNASDAQ:HYPRNASDAQ:ICCMNASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDAPEDAP TMS$1.60+1.6%$1.87$1.26▼$5.27$58.71MN/A98,569 shs22,749 shsHYPRHyperfine$0.79+8.8%$0.70$0.53▼$1.90$56.44M1.01900,761 shs408,654 shsICCMIceCure Medical$1.06+4.9%$1.04$0.48▼$1.66$56.06M0.31478,627 shs581,707 shsPSTVPlus Therapeutics$0.30-3.6%$0.41$0.16▼$2.31$15.67M0.6910.03 million shs4.14 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDAPEDAP TMS-5.99%-11.30%-13.38%-17.80%-70.38%HYPRHyperfine+5.48%+1.06%-14.69%+4.97%-24.85%ICCMIceCure Medical-0.98%-0.98%-3.81%-17.89%+36.25%PSTVPlus Therapeutics-0.94%-2.48%-16.45%-60.36%-80.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDAPEDAP TMS2.4145 of 5 stars3.25.00.00.00.01.70.6HYPRHyperfine1.9068 of 5 stars3.32.00.00.00.02.50.6ICCMIceCure Medical2.128 of 5 stars3.84.00.00.00.00.00.6PSTVPlus Therapeutics1.6867 of 5 stars3.32.00.00.02.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDAPEDAP TMS 2.33Hold$8.50432.92% UpsideHYPRHyperfine 2.67Moderate Buy$1.0634.35% UpsideICCMIceCure Medical 3.50Strong Buy$2.50136.07% UpsidePSTVPlus Therapeutics 2.50Moderate Buy$10.833,559.91% UpsideCurrent Analyst Ratings BreakdownLatest PSTV, EDAP, HYPR, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.50 ➝ $3.006/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold$9.006/5/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $20.506/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/29/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.505/15/2025EDAPEDAP TMSPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.685/5/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDAPEDAP TMS$69.18M0.86N/AN/A$1.18 per share1.35HYPRHyperfine$12.89M4.76N/AN/A$0.67 per share1.18ICCMIceCure Medical$3.29M17.86N/AN/A$0.12 per share8.83PSTVPlus Therapeutics$5.82M2.59N/AN/A($1.52) per share-0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDAPEDAP TMS-$20.58M-$0.62N/AN/AN/A-34.45%-51.42%-26.43%8/27/2025 (Estimated)HYPRHyperfine-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/6/2025 (Estimated)ICCMIceCure Medical-$15.32M-$0.28N/AN/AN/A-467.37%-182.26%-112.65%8/19/2025 (Estimated)PSTVPlus Therapeutics-$12.98M-$2.94N/AN/AN/A-520.90%N/A-202.73%8/13/2025 (Estimated)Latest PSTV, EDAP, HYPR, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025PSTVPlus Therapeutics-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million5/28/2025Q1 2025ICCMIceCure Medical-$0.08-$0.06+$0.02-$0.06$0.75 million$0.73 million5/15/2025Q1 2025EDAPEDAP TMS-$0.16-$0.20-$0.04-$0.20$16.56 million$16.37 million5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDAPEDAP TMSN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDAPEDAP TMS0.101.741.21HYPRHyperfineN/A6.075.48ICCMIceCure Medical0.021.891.48PSTVPlus TherapeuticsN/A1.031.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDAPEDAP TMS62.74%HYPRHyperfine15.03%ICCMIceCure Medical0.62%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipEDAPEDAP TMS0.23%HYPRHyperfine30.98%ICCMIceCure Medical2.44%PSTVPlus Therapeutics3.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDAPEDAP TMS23037.39 million37.31 millionOptionableHYPRHyperfine19077.83 million53.72 millionOptionableICCMIceCure Medical6055.50 million54.15 millionNot OptionablePSTVPlus Therapeutics2051.00 million49.08 millionNot OptionablePSTV, EDAP, HYPR, and ICCM HeadlinesRecent News About These CompaniesPSTV - Plus Therapeutics Inc Trailing Returns - MorningstarJuly 2 at 10:39 AM | morningstar.comMPlus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal MetastasesJune 30 at 7:30 AM | globenewswire.comPlus Therapeutics (NASDAQ:PSTV) Price Target Cut to $3.00 by Analysts at HC WainwrightJune 28, 2025 | americanbankingnews.comD. Boral Capital Reiterates Hold Rating for Plus Therapeutics (NASDAQ:PSTV)June 27, 2025 | americanbankingnews.comPlus Therapeutics Provides Business Update on CNSide Diagnostics SubsidiaryJune 26, 2025 | globenewswire.comPlus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ETJune 25, 2025 | globenewswire.comPlus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain CancerJune 25, 2025 | globenewswire.comPlus Therapeutics Restructures Financing to Eliminate Potential Dilution of 1.5 Billion SharesJune 24, 2025 | quiverquant.comQPlus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity FinancingJune 24, 2025 | globenewswire.comPlus (PSTV) Upgraded to Buy: Here's WhyJune 19, 2025 | zacks.comPlus Therapeutics Modifies Security Holders’ RightsJune 17, 2025 | tipranks.comPlus Therapeutics Reports First Quarter Financial Results and Recent Business HighlightsMay 30, 2025 | finance.yahoo.comPlus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue EstimatesMay 30, 2025 | zacks.comPlus Therapeutics, Inc. Reports Q1 2025 Financial Results and Updates on REYOBIQ™ Trials and CNSide® Assay Platform ProgressMay 30, 2025 | quiverquant.comQPlus Therapeutics Reports First Quarter Financial Results and Recent Business HighlightsMay 30, 2025 | globenewswire.comPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed ...May 23, 2025 | gurufocus.comPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-QMay 23, 2025 | globenewswire.comPlus Therapeutics reports progress in CNS cancer therapyMay 15, 2025 | investing.comPlus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)May 15, 2025 | finance.yahoo.comPlus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 14, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSTV, EDAP, HYPR, and ICCM Company DescriptionsEDAP TMS NASDAQ:EDAP$1.60 +0.03 (+1.59%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.Hyperfine NASDAQ:HYPR$0.79 +0.06 (+8.81%) Closing price 03:55 PM EasternExtended Trading$0.78 -0.01 (-0.76%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.IceCure Medical NASDAQ:ICCM$1.06 +0.05 (+4.85%) Closing price 03:46 PM EasternExtended Trading$1.06 0.00 (-0.38%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Plus Therapeutics NASDAQ:PSTV$0.30 -0.01 (-3.65%) Closing price 03:59 PM EasternExtended Trading$0.30 +0.00 (+0.34%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
